Rapport Therapeutics, Inc. RAPP Proceeds From Sale Of Short Term Investments

Proceeds From Sale Of Short Term Investments at other companies

Monolithic Power SystemsMPWR

$14.44M-89.8%

CSXCSX

$5M-92.5%

Southern CopperSCCO

$423.58M+75.4%

FedExFDX

$27.5M+189%

Electronic ArtsEA

$42M-87.2%

Advanced Micro DevicesAMD

$126M+282%

Other financials

Income statement

See full

Revenue$20.0M—

Operating income-$24.2M+10.7%

Net income-$19.9M+17.5%

EPS (diluted)-$0.42+38.2%

Balance sheet

See full

Cash & equivalents$78.1M+35.5%

Total debt$10.8M+37.8%

Total equity$471.5M+65.0%

Total assets$497.6M+64.7%

Cash flow

See full

Operating cash flow-$13.1M+35.5%

CapEx$86.0K-70.4%

Free cash flow-$13.1M+36.0%

Valuation

See full

Market cap$1.91B+309%

Returns & leverage

See full

Return on equity-28.3%—

Debt / equity0×0.0×

Current ratio27.1×-3.9×

Where this comes from

Reported directly by Rapport Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfShortTermInvestments.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s proceeds from sale of short term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s proceeds from sale of short term investments?: Rapport Therapeutics, Inc. (RAPP) reported proceeds from sale of short term investments of $10.08M in Q1 2026.